[Ip-health] Fwd: Letter to India's new IPR Think Tank on IP and Access to Medicines

leena menghaney leenamenghaney at gmail.com
Tue Dec 2 07:16:45 PST 2014


Global Sign-On Letter to India's new IPR Think Tank on IP and Access
to Medicines

A letter to India's newly constituted IPR Think Tank, signed by patient
groups, public interest organisations, treatment providers and academia
world-wide, raises critical issues around the intellectual property system
in India. A particular area of concern is pharmaceuticals, as India is a
key global supplier of affordable generic versions of drugs that otherwise
would be out of reach for public health programmes, treatment providers and
millions of people.

In the present context of heightened US pressure on India's government,
and in particular on India's Department of Industrial Policy and
Promotion (DIPP), the letter signatories oppose any re-opening of the
discussion on
patentability criteria, interpretation of Indian patent law, or
the introduction of TRIPS-plus standards, which would provide
multinational pharmaceutical companies and the US Trade Representative an
opportunity to take forward their agenda to undermine generic competition
from India at the expense of public health safeguards in India's patent law
and its negotiating position in various bilateral and international forums.

Any examination of IP issues by India's new IPR Think Tank must not
further undermine access to medicines or India's standing as the pharmacy
of the developing world, on which millions of people around the world rely.
The
letter can be accessed here:

http://www.msfaccess.org/sites/default/files/letter_Global_IP%20and%20access
%20to%20medicines_India%20IP%20Think%20Tank.pdf



Leena Menghaney
Mobile: 9811365412



More information about the Ip-health mailing list